Takeda Pharmaceutical Company Limited (TKDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Takeda Pharmaceutical Company Limited (TKDA) has a cash flow conversion efficiency ratio of 0.053x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€378.23 Billion) by net assets (€7.13 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Takeda Pharmaceutical Company Limited - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Takeda Pharmaceutical Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Takeda Pharmaceutical Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Takeda Pharmaceutical Company Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Block, Inc
NYSE:XYZ
|
0.065x |
|
ArcelorMittal SA
MC:MTS
|
0.056x |
|
Oil & Natural Gas Corporation Limited
NSE:ONGC
|
0.151x |
|
Hartford Financial Services Group
NYSE:HIG
|
0.097x |
|
Marubeni Corporation
F:MAR0
|
N/A |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-A
|
0.151x |
|
Erste Group Bank AG
VI:EBS
|
0.088x |
|
JD.com Inc.
F:013C
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Takeda Pharmaceutical Company Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Takeda Pharmaceutical Company Limited from 2017 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | €6.94 Trillion | €1.06 Trillion | 0.152x | +54.77% |
| 2024-03-31 | €7.27 Trillion | €716.34 Billion | 0.098x | -35.96% |
| 2023-03-31 | €6.35 Trillion | €977.16 Billion | 0.154x | -22.18% |
| 2022-03-31 | €5.68 Trillion | €1.12 Trillion | 0.198x | +1.20% |
| 2021-03-31 | €5.18 Trillion | €1.01 Trillion | 0.195x | +37.83% |
| 2020-03-31 | €4.73 Trillion | €669.75 Billion | 0.142x | +122.70% |
| 2019-03-31 | €5.16 Trillion | €328.48 Billion | 0.064x | -66.04% |
| 2018-03-31 | €2.02 Trillion | €377.85 Billion | 0.187x | +39.67% |
| 2017-03-31 | €1.95 Trillion | €261.36 Billion | 0.134x | -- |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more